Approaches to the management of relapsed/refractory mantle cell lymphoma: navigating an increasingly complex therapeutic landscape

EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma

Recent advances and future directions in newly diagnosed mantle cell lymphoma

Pharmaceutical Benefits Advisory Committee Recommendations Announced

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

“The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors

GOlDiLOX: A World-First Combination

Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse

Therapeutic Options for Relapsed/Refractory Mantle Cell Lymphoma